NCT06125652View on ClinicalTrials.gov

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Interventions
DRUG

anti Tim-3/CD123 CAR-T cell therapy

Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Trial Locations (1)

221000

RECRUITING

Kailin Xu, Xuzhou

All Listed Sponsors
lead

Xuzhou Medical University

OTHER